Navigation Links
Cardiovascular Systems Announces Plans for Second Manufacturing Facility - New Facility Expands CSI's Capacity to Produce Peripheral Arterial Disease Systems
Date:10/7/2009

rocedures have been performed using the Diamondback 360°.

CSI received $3.5 million upon the signing of the lease and could receive up to an additional $3.5 million over five years as milestones are met. CSI expects to begin operations in the facility during the first half of calendar 2010. Pearland was selected as the best location for the Diamondback 360° facility after an extensive search process lead by Ecodev, LLC, a site selection firm recognized for successfully uniting companies and communities in partnerships for sustainable economic growth.

About Cardiovascular Systems, Inc.

Cardiovascular Systems, Inc., based in St. Paul, Minn., is a medical device company focused on developing and commercializing interventional treatment systems for vascular disease. The company's Diamondback 360® PAD System treats calcified and fibrotic plaque in arterial vessels throughout the leg, and addresses many of the limitations associated with existing surgical, catheter and pharmacological treatment alternatives. In August 2007, the U.S. FDA granted 510(k) clearance for the use of the Diamondback 360° as a therapy for PAD (peripheral arterial disease), and CSI commenced a U.S. product launch in September 2007. Since then, nearly 600 hospitals across the United States have adopted the system. For more information visit the company's Web site at www.csi360.com.

Safe Harbor

Certain statements in this news release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and are provided under the protection of the safe harbor for forward-looking statements provided by that Act. For example, statements in this press release regarding (i) CSI's need for additional ma
'/>"/>

Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. 8 Ounces a Day of POM Wonderful 100% Pomegranate Juice May Slow Progression of Carotid Intima-Media Thickness (CIMT) in Patients with Elevated Cardiovascular Disease Risk Factors, Study Finds
2. BUSM researchers propose a relationship between androgen deficiency and cardiovascular disease
3. MAQUET Cardiovascular Receives FDA Clearance for MEGA(TM), the Worlds First 8Fr. 50cc Intra-Aortic Balloon Catheter
4. Cardiogenesis Announces Successful Symposium at the Transcatheter Cardiovascular Therapeutics (TCT) Meeting
5. Novel Information about Vulnerable Coronary Artery Plaque to be Presented at Transcatheter Cardiovascular Therapeutics (TCT) 2009
6. Health Leaders Issue Recommendations to Improve Management of a Common, Costly and Misunderstood Cardiovascular Disease: Atrial Fibrillation
7. Dr. Eliscer Guzman, with The Mount Sinai Medical Center, Join Forces to Celebrate the Community Diabetes and Cardiovascular Care Programs Graduation Ceremony on September 16th
8. Finding of genetic region controlling cardiovascular sensitivity to anesthetic propofol
9. Expanded Cardiovascular Care Services on Long Island
10. Lead in bone associated with increased risk of death from cardiovascular disease in men
11. Researchers link inflammatory diseases to increased cardiovascular risk
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2009)... it,s still too early to say that ... TUESDAY, Dec. 15 (HealthDay News) -- Common chemicals ... to the abnormal growth of breasts in boys, ... in a prominent medical journal for pediatricians, adds ... phthalates, whose safety has been questioned by some ...
(Date:12/15/2009)... when doctors decide benefits of imaging outweigh the risks ... can pose a serious risk to people with heart ... researchers exposed pacemakers to a simulated MRI magnetic field ... tip of the pacemaker lead, where it would touch ... to MRI magnetic pulses caused certain pacemakers to deliver ...
(Date:12/15/2009)... Accelify is proud to announce the addition ... David will serve as Director of Development in the ... Board of Advisors. ,, David Tokofsky was ... of Education in June 1995. As the Board Member ... 600,000 stretching from Northeast Los Angeles through East Los ...
(Date:12/15/2009)... and acquisitions are commonplace today. As competitors come ... a product portfolio they also must face integration ... A new free, white paper from Howard Leight ... Program: US Airways ," details how the merger ... newly formed company to enhance its occupational Hearing ...
(Date:12/15/2009)... -- Reportlinker.com announces that a new ... its catalogue: ,, The ... Market Forecasts to 2015, Competitive Benchmarking, ... ,, http://www.reportlinker.com/p0168100/The-Future-of-Autoimmune-Diseases-Therapeutics---Market-Forecasts-to-2015-Competitive-Benchmarking-Product-Pipeline-and-Deals-Analysis.html ,, ... has released its latest research "The ...
Breaking Medicine News(10 mins):Health News:Breast Growth in Boys Might Be Linked to Plastics Chemical 2Health News:Breast Growth in Boys Might Be Linked to Plastics Chemical 3Health News:Patients With Pacemakers Should Avoid MRI Scans 2Health News:Accelify Announces the Addition of David Tokofsky to its National Board of Advisors 2Health News:New White Paper Details Best Practices of an Occupational Hearing Conservation Program: US Airways 2Health News:New White Paper Details Best Practices of an Occupational Hearing Conservation Program: US Airways 3Health News:New White Paper Details Best Practices of an Occupational Hearing Conservation Program: US Airways 4Health News:Reportlinker Adds The Future of Autoimmune Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 2Health News:Reportlinker Adds The Future of Autoimmune Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 3Health News:Reportlinker Adds The Future of Autoimmune Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 4Health News:Reportlinker Adds The Future of Autoimmune Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 5Health News:Reportlinker Adds The Future of Autoimmune Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 6Health News:Reportlinker Adds The Future of Autoimmune Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 7Health News:Reportlinker Adds The Future of Autoimmune Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 8Health News:Reportlinker Adds The Future of Autoimmune Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 9Health News:Reportlinker Adds The Future of Autoimmune Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 10Health News:Reportlinker Adds The Future of Autoimmune Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 11Health News:Reportlinker Adds The Future of Autoimmune Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 12Health News:Reportlinker Adds The Future of Autoimmune Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 13Health News:Reportlinker Adds The Future of Autoimmune Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 14Health News:Reportlinker Adds The Future of Autoimmune Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 15Health News:Reportlinker Adds The Future of Autoimmune Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 16Health News:Reportlinker Adds The Future of Autoimmune Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 17Health News:Reportlinker Adds The Future of Autoimmune Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 18Health News:Reportlinker Adds The Future of Autoimmune Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 19Health News:Reportlinker Adds The Future of Autoimmune Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 20Health News:Reportlinker Adds The Future of Autoimmune Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 21Health News:Reportlinker Adds The Future of Autoimmune Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 22Health News:Reportlinker Adds The Future of Autoimmune Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 23
... the PSSIG for a Three-Year TermSAN FRANCISCO, Jan. 22 ... Rashidee, Quantros Director for Safety and Risk Management, has ... Interest Group (PSSIG). This international organization,s ongoing mission is ... applications for the exchange of key sets of clinical ...
... Travel Advantage Network , one of the nation,s fastest-growing ... G. Komen for the Cure , the global leader of ... sales and a Jeans Day, where employees purchase the opportunity ... raised $729 for Susan G. Komen for the Cure, the ...
... Jan. 22 McAuley Ministries, the new grant-making arm ... its first grant... and the recipient is the YMCA ... fund the construction of a green rooftop terrace for ... "The new Thelma Lovette YMCA touches several of McAuley ...
... announced today that,the physicians of Midwest Pulmonary and ... , The physicians are Susan ... Plumb, M.D. All are board-certified in pulmonology,and critical care ... the treatment of sleep disorders. , ...
... Hurricane Katrina, the health of survivors 65 and over ... of older adults not affected by the disaster, according ... Hopkins Bloomberg School of Public Health. The August 2005 ... hurricanes in U.S. history. Hurricane Katrina displaced thousands and ...
... longtime director of the HIV advocacy/education organization Project Inform, ... and Infectious Diseases (NIAID) Director,s Special Recognition Award for ... , Mr. Delaney in 1985 founded Project Inform, ... and advocacy organization based in San Francisco, and served ...
Other Medicine News:Health News:Quantros Director of Patient Safety and Risk Management is Elected Co-Chair of Patient Safety Special Interest Group (PSSIG) at HL7 2Health News:Quantros Director of Patient Safety and Risk Management is Elected Co-Chair of Patient Safety Special Interest Group (PSSIG) at HL7 3Health News:Grassroots Group Gets Travel Advantage Network Support 2Health News:YMCA of Greater Pittsburgh Receives $500,000 from McAuley Ministries for New Hill YMCA Roof 2Health News:YMCA of Greater Pittsburgh Receives $500,000 from McAuley Ministries for New Hill YMCA Roof 3Health News:Midwest Pulmonary and Critical Care Associates Will Join Aurora Medical Group 2Health News:Decline in health among older adults affected by Hurricane Katrina 2Health News:NIAID honors AIDS activist Martin Delaney 2
(Date:12/15/2009)... PARK, Calif., Dec. 15 SRI International, ... today the award of U.S. patent 7,592,021 for ... enhanced release of drugs through the human body,s ... drug delivery and allows for a much longer ... or liquids. ,, Transmucosal delivery is an effective ...
(Date:12/15/2009)... medical expert internationally recognized as a leading authority ... last month to suspend Doug Barron for doping ... the medical condition hypogonadism and was ... and discriminatory." ,, Hypogonadism is the ... referred to informally as Low T . ...
(Date:12/15/2009)... -- Fenwal Inc., a global medical technology company ... availability, announced today that the U.S. Food and ... InterSol ® platelet additive solution. Fenwal ... specialized product used in combination with human plasma ... used to prevent or treat bleeding. ,, InterSol ...
Breaking Medicine Technology:SRI International Receives U.S. Patent for Needle-Free Transmucosal Drug Delivery System 2SRI International Receives U.S. Patent for Needle-Free Transmucosal Drug Delivery System 3SRI International Receives U.S. Patent for Needle-Free Transmucosal Drug Delivery System 4SRI International Receives U.S. Patent for Needle-Free Transmucosal Drug Delivery System 5Harvard Medical Expert Criticizes PGA Tour, Calls Decision to Suspend Doug Barron for Doping 'Unreasonable, Unfair and Discriminatory' 2Harvard Medical Expert Criticizes PGA Tour, Calls Decision to Suspend Doug Barron for Doping 'Unreasonable, Unfair and Discriminatory' 3Harvard Medical Expert Criticizes PGA Tour, Calls Decision to Suspend Doug Barron for Doping 'Unreasonable, Unfair and Discriminatory' 4Fenwal Receives FDA Approval for New Solution Used to Store Donated Blood Platelets 2SearchAmerica 28R 29 President Daniel Johnson Named Ernst 26 Young Entrepreneur Of The Year 28R 29 50424 1SearchAmerica 28R 29 President Daniel Johnson Named Ernst 26 Young Entrepreneur Of The Year 28R 29 50424 2SearchAmerica 28R 29 President Daniel Johnson Named Ernst 26 Young Entrepreneur Of The Year 28R 29 50424 3Wisconsin Tobacco Tax Increase Is Positive Step for Health but Budget Disappoints by Cutting Funding for Tobacco Prevention Programs 50421 1Wisconsin Tobacco Tax Increase Is Positive Step for Health but Budget Disappoints by Cutting Funding for Tobacco Prevention Programs 50421 2Wisconsin Tobacco Tax Increase Is Positive Step for Health but Budget Disappoints by Cutting Funding for Tobacco Prevention Programs 50421 3Over One Thousand Blind Americans to March in Detroit 50418 1Over One Thousand Blind Americans to March in Detroit 50418 2
... Developed Through Joint Venture Between Bristol-Myers Squibb and ... of Its Kind in HIV Treatment -, PRINCETON, ... European Commission has granted marketing authorization for,ATRIPLA(R) (efavirenz 600 ... for commercialization in the,27 countries of the European Union, ...
... into Treatment Impact, Node-Positive ... Breast Cancer, Measuring ER/PR Scores, REDWOOD CITY, Calif., Dec. ... results from multiple studies,reinforcing the clinical utility of the company,s ... recurrence and the,likelihood of chemotherapy benefit for a large portion ...
Other Medicine Technology:European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection 2European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection 3European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection 4European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection 5European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection 6European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection 7European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection 8European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection 9Multiple Studies Presented at San Antonio Breast Cancer Symposium Reinforce Clinical Utility of Oncotype DX(R) 2Multiple Studies Presented at San Antonio Breast Cancer Symposium Reinforce Clinical Utility of Oncotype DX(R) 3Multiple Studies Presented at San Antonio Breast Cancer Symposium Reinforce Clinical Utility of Oncotype DX(R) 4Multiple Studies Presented at San Antonio Breast Cancer Symposium Reinforce Clinical Utility of Oncotype DX(R) 5Multiple Studies Presented at San Antonio Breast Cancer Symposium Reinforce Clinical Utility of Oncotype DX(R) 6Multiple Studies Presented at San Antonio Breast Cancer Symposium Reinforce Clinical Utility of Oncotype DX(R) 7
... BAK/C cervical interbody fusion system represents a ... of the cervical spine. The system gathers ... implantation. The self-packing of bone into the ... the need to harvest from the iliac ...
Signa Profile is built on the Signa foundation to deliver speed & image quality....
... instrument set consisting of 38 cobbs, ... in the spine. The instruments extra ... These instruments, best applied in thoracic, ... ideal option for surgeons to pick ...
... has an extensive base of experience and ... gel. When concentrated autologous platelets are mixed ... and functional changes involved in coagulation take ... number of factors including serotonin, fibronectin, adenosine ...
Medicine Products: